Laura Tadvalkar, PhD

Managing Director, Venture

Name: RA Capital
Price range: $

Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Laura works on new company creation and early-stage investments, and serves as a Board Director for Typewriter Therapeutics, GIVAX, Imbria Pharmaceuticals, Serapha Bio, and NorthLinks Bio. She previously served as a Board Director for Mariana Oncology prior to its acquisition by Novartis and as Board Chair for Aliada Therapeutics prior to its acquisition by AbbVie. Prior to RA Capital, Laura was a Principal at MP Healthcare Venture Management and a Consultant at Clarion Healthcare. Laura holds a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University.

Department: Healthcare
Degree: PhD
Joined: 2020
University / College: Yale University, Harvard University